|
- 2018
Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancerAbstract: Colorectal cancer (CRC) is the third common cause of malignancy in the world. The incidence and death rate from this cancer has a trend increasingly, especially in developing countries (1). Chemotherapy and radiation therapy (RT) are considered as appropriated pre-operative and post-operative treatments for locally advanced rectal cancer (LARC), stage II (T3–4N0M0) and III (T1–4N1–2M0). Intravenous administration of 5-fluorouracil (5-FU)-based regimen or oral administration of fluoropyrimidine as capecitabine is commonly used in concurrent time with RT and adjuvant treatment. In 2012, a landmark study from Germany reported that capecitabine could be substituted for 5-FU in pre-operative or post-operative setting for rectal cancer because of its non-inferiority of efficacy and less hemato-toxicity than 5-FU (2). Therefore, capecitabine is proved to be used as an adjuvant setting in NCCN guideline for rectal cancer (3)
|